News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
602,624 Results
Type
Article (46526)
Company Profile (196)
Press Release (555902)
Section
Business (172317)
Career Advice (2526)
Deals (31820)
Drug Delivery (122)
Drug Development (76087)
Employer Resources (156)
FDA (16177)
Job Trends (13253)
News (304832)
Policy (31801)
Tag
Academia (2359)
Alliances (43251)
Alzheimer's disease (1393)
Approvals (16130)
Artificial intelligence (219)
Bankruptcy (319)
Best Places to Work (9921)
Breast cancer (229)
Cancer (1746)
Cardiovascular disease (140)
Career advice (2109)
CAR-T (127)
Cell therapy (373)
Clinical research (61439)
Collaboration (651)
Compensation (387)
COVID-19 (2631)
C-suite (173)
Data (1606)
Diabetes (226)
Diagnostics (5500)
Earnings (68118)
Employer resources (141)
Events (90753)
Executive appointments (564)
FDA (17124)
Funding (552)
Gene therapy (273)
GLP-1 (751)
Government (3926)
Healthcare (15466)
Infectious disease (2753)
Inflammatory bowel disease (123)
Interviews (463)
IPO (15047)
Job creations (3756)
Job search strategy (1767)
Layoffs (490)
Legal (7695)
Lung cancer (256)
Manufacturing (254)
Medical device (11375)
Medtech (11379)
Mergers & acquisitions (17165)
Metabolic disorders (633)
Neuroscience (1833)
NextGen: Class of 2025 (5275)
Non-profit (3320)
Northern California (2082)
Obesity (357)
Opinion (232)
Patents (178)
People (50737)
Phase I (18442)
Phase II (26749)
Phase III (21223)
Pipeline (800)
Postmarket research (2551)
Preclinical (7585)
Radiopharmaceuticals (227)
Rare diseases (347)
Real estate (5201)
Regulatory (22064)
Research institute (2184)
Resumes & cover letters (416)
Southern California (1762)
Startups (3237)
United States (17915)
Vaccines (700)
Weight loss (273)
Date
Today (132)
Last 7 days (797)
Last 30 days (2743)
Last 365 days (32738)
2025 (5312)
2024 (33288)
2023 (37222)
2022 (47704)
2021 (51385)
2020 (48650)
2019 (39201)
2018 (29904)
2017 (30547)
2016 (29175)
2015 (32677)
2014 (26562)
2013 (22192)
2012 (23752)
2011 (24429)
2010 (22346)
Location
Africa (760)
Arizona (169)
Asia (37074)
Australia (6068)
California (4683)
Canada (1489)
China (382)
Colorado (219)
Connecticut (245)
Europe (84613)
Florida (705)
Georgia (151)
Illinois (406)
Indiana (231)
Japan (123)
Maryland (739)
Massachusetts (3603)
Michigan (168)
Minnesota (290)
New Jersey (1360)
New York (1307)
North Carolina (843)
Northern California (2082)
Ohio (145)
Pennsylvania (1029)
South America (1133)
Southern California (1762)
Texas (668)
Utah (131)
Washington State (449)
602,624 Results for "rhizen pharmaceuticals s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022
Rhizen Pharma announces presentations at AACR showcasing its differentiated clinical stage PARP and DHODH programs Preclinical data on Rhizen’s differentiated PARP inhibitor RP12146, indicates a superior haematological safety profile that the company expects will translate through ongoing clinical trials.
April 9, 2022
·
5 min read
Press Releases
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
February 24, 2025
·
5 min read
Press Releases
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
February 20, 2025
·
5 min read
Rhizen Pharmaceuticals AG Announces Upcoming Data Presentations at ESMO 2022 for Its Clinical Stage Assets; Tenalisib in Locally Advanced/ Metastatic Breast Cancer and RP12146 in Multiple Solid Tumors
Rhizen Pharmaceuticals AG, a Swiss based privately held, clinical-stage biopharmaceutical company announced that it is presenting data from an ongoing Phase 2 trial of Tenalisib in locally advanced or metastatic breast cancer and data from a concluded dose escalation phase of RP12146 at ESMO 2022, Paris from Sept 9-13, 2022.
September 9, 2022
·
4 min read
Press Releases
Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
February 27, 2025
·
1 min read
Press Releases
U.S. Pharmaceutical Market Size to Hit USD 1,107.4 Billion by 2034
February 26, 2025
·
1 min read
Press Releases
U.S. Pharmaceutical Water Market Size to Surpass USD 16,950 Mn by 2034
February 25, 2025
·
1 min read
Press Releases
U.S. Pharmaceutical CDMO Market Size to Surpass USD 84.33 Bn by 2034
February 25, 2025
·
1 min read
Press Releases
Boehringer Ingelheim Pharmaceuticals, Inc. Welcomes Brian Hilberdink as President, U.S. Human Pharma
February 20, 2025
·
2 min read
Press Releases
Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women’s Health and Dermatology
February 21, 2025
·
5 min read
1 of 60,263
Next
